​

10x Genomics (TXG) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

TXG Stock Forecast

10x Genomics (TXG) stock forecast, based on 21 Wall Street analysts, predicts a 12-month average price target of $30.20, with a high of $46.00 and a low of $24.00. This represents a 115.71% increase from the last price of $14.00.

$10 $20 $30 $40 $50 $60 High: $46 Avg: $30.2 Low: $24 Last Closed Price: $14

TXG Stock Rating

10x Genomics stock's rating consensus is Buy, based on 21 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 12 Buy (57.14%), 8 Hold (38.10%), 1 Sell (4.76%), and 0 Strong Sell (0.00%).

Buy
Total 21 0 1 8 12 Strong Sell Sell Hold Buy Strong Buy

TXG Price Target Upside V Benchmarks

TypeNameUpside
Stock10x Genomics115.71%
SectorHealthcare Stocks 19.91%
IndustryHealthcare Information Services Stocks 24.43%

Price Target Trends

1M3M12M
# Anlaysts--1
Avg Price Target--$46.00
Last Closing Price$14.00$14.00$14.00
Upside/Downside--228.57%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jul, 25259--16
Jun, 25259-117
May, 25258-116
Apr, 25258-116
Mar, 25259-117
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Aug 13, 2024Tejas SavantMorgan Stanley$46.00$19.65134.10%228.57%
Jul 23, 2024Kyle MiksonCanaccord Genuity$32.00$18.1176.70%128.57%
Jul 10, 2024Justin BowersDeutsche Bank$25.00$18.2536.99%78.57%
Jun 28, 2024Luke SergottBarclays$24.00$19.8520.91%71.43%
Jun 03, 2024Tycho PetersonJefferies$24.00$22.427.05%71.43%
May 01, 2024Luke SergottBarclays$36.00$29.2822.95%157.14%
Apr 10, 2024Luke SergottBarclays$45.00$37.3720.42%221.43%
Dec 14, 2022Deutsche Bank$50.00$35.2142.01%257.14%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jun 24, 2025BarclaysOverweightOverweighthold
Oct 30, 2024UBSNeutralNeutralhold
Oct 16, 2024Cowen & Co.HoldHoldhold
Oct 10, 2024UBSBuyBuyhold
Sep 03, 2024UBSBuyBuyhold
Aug 13, 2024UBSBuyBuyhold
Jul 22, 2024JefferiesHoldBuyupgrade
Jul 10, 2024Deutsche BankBuyHolddowngrade
Jun 28, 2024BarclaysOverweightOverweighthold
Jun 27, 2024Wolfe ResearchPeer Performdowngrade

Financial Forecast

EPS Forecast

$-6 $-5 $-4 $-3 $-2 $-1 $0 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-5.37$-0.53$-1.46$-2.18$-1.52----
Avg Forecast$-1.47$-0.46$-1.62$-2.14$-1.41$-1.27$-0.91$-0.86$-1.07
High Forecast$-1.35$-0.43$-1.55$-1.73$-1.35$-1.12$-0.04$-0.71$-1.01
Low Forecast$-1.57$-0.49$-1.68$-2.31$-1.47$-1.52$-1.41$-1.09$-1.13
Surprise %265.31%15.22%-9.88%1.87%7.80%----

Revenue Forecast

$250M $370M $490M $610M $730M $850M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$298.85M$490.49M$516.41M$618.73M$610.78M----
Avg Forecast$286.92M$493.74M$508.11M$616.72M$604.92M$630.74M$687.60M$739.28M$791.90M
High Forecast$301.81M$519.37M$521.63M$617.30M$611.79M$659.73M$688.66M$746.52M$829.91M
Low Forecast$268.82M$462.60M$491.46M$615.68M$598.81M$608.74M$686.53M$732.03M$761.89M
Surprise %4.16%-0.66%1.63%0.32%0.97%----

Net Income Forecast

$-7B $-6B $-4B $-3B $-1B $0 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-542.73M$-58.22M$-166.00M$-255.10M$-182.63M----
Avg Forecast$-5.67B$-64.96M$-86.08M$-255.10M$-165.42M$-158.30M$-119.69M$-105.37M$-124.98M
High Forecast$-4.54B$-51.97M$-68.86M$-204.08M$-158.48M$-131.42M$-4.13M$-83.35M$-118.82M
Low Forecast$-6.81B$-77.95M$-103.29M$-306.12M$-172.36M$-177.53M$-165.29M$-127.39M$-132.77M
Surprise %-90.43%-10.37%92.85%-10.40%----

TXG Forecast FAQ

Is 10x Genomics stock a buy?

10x Genomics stock has a consensus rating of Buy, based on 21 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 12 Buy, 8 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that 10x Genomics is a favorable investment for most analysts.

What is 10x Genomics's price target?

10x Genomics's price target, set by 21 Wall Street analysts, averages $30.2 over the next 12 months. The price target range spans from $24 at the low end to $46 at the high end, suggesting a potential 115.71% change from the previous closing price of $14.

How does 10x Genomics stock forecast compare to its benchmarks?

10x Genomics's stock forecast shows a 115.71% upside, outperforming the average forecast for the healthcare stocks sector (19.91%) and outperforming the healthcare information services stocks industry (24.43%).

What is the breakdown of analyst ratings for 10x Genomics over the past three months?

  • July 2025: 12.50% Strong Buy, 31.25% Buy, 56.25% Hold, 0% Sell, 0% Strong Sell.
  • June 2025: 11.76% Strong Buy, 29.41% Buy, 52.94% Hold, 0% Sell, 5.88% Strong Sell.
  • May 2025: 12.50% Strong Buy, 31.25% Buy, 50.00% Hold, 0% Sell, 6.25% Strong Sell.

What is 10x Genomics’s EPS forecast?

10x Genomics's average annual EPS forecast for its fiscal year ending in December 2025 is $-1.27, marking a -16.45% decrease from the reported $-1.52 in 2024. Estimates for the following years are $-0.91 in 2026, $-0.86 in 2027, and $-1.07 in 2028.

What is 10x Genomics’s revenue forecast?

10x Genomics's average annual revenue forecast for its fiscal year ending in December 2025 is $630.74M, reflecting a 3.27% increase from the reported $610.78M in 2024. The forecast for 2026 is $687.6M, followed by $739.28M for 2027, and $791.9M for 2028.

What is 10x Genomics’s net income forecast?

10x Genomics's net income forecast for the fiscal year ending in December 2025 stands at $-158M, representing a -13.32% decrease from the reported $-183M in 2024. Projections indicate $-120M in 2026, $-105M in 2027, and $-125M in 2028.